Overweight or obesity
Conditions
Interventions
Obesity or overweight observation group:None
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18 - 60 years old (inclusive of the threshold value, based on the date of signing the informed consent form); 2. Gender is not restricted; 3. Body Mass Index (BMI) >= 24 kg/m^2 and = 28 kg/m^2 (comorbidities include endocrine and metabolic systems such as type 2 diabetes, lipid disorders, hyperuricemia; respiratory system such as obstructive sleep apnea syndrome; cardiovascular system such as coronary atherosclerotic heart disease, hypertension; urinary system such as chronic kidney disease, stress urinary incontinence; reproductive system such as polycystic ovary syndrome; digestive system such as gastroesophageal reflux disease, metabolic dysfunction-related fatty liver; skeletal and movement system such as osteoarthritis; psychological disorders such as depression, anxiety, etc.); 4. Selected from patients who have used telaprevir; 5. From the date of signing the informed consent until the study follow-up period, there is no intention to have children, and voluntarily take effective physical contraceptive measures, and no sperm donation plan; 6. The patient fully understands the purpose, nature, methods of the trial, as well as possible adverse reactions, voluntarily participates in this study, and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Screening for the history of using weight loss drugs within the past 3 months; 2. Screening for those who have used GLP-1 receptor agonists/antagonists or dipeptidyl peptidase IV inhibitors within the past 3 months; 3. Having a history of bariatric surgery; 4. Severe hypertension, with systolic blood pressure (SBP) >= 180 mmHg and/or diastolic blood pressure (DBP) >= 120 mmHg; 5. Having a history of acute or chronic pancreatitis, a symptomatic history of gallbladder disease (such as multiple gallbladder stones), a history of pancreatic injury, etc., which are high-risk factors that may cause pancreatitis; 6. Having a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2A or 2B syndrome, or related family history; 7. Known to be allergic to the active ingredients of the study drug (GLP-1 and GLP-1RA); 8. Any other situation that the researcher considers may affect the patient's ability to provide informed consent or follow the trial protocol, or the patient's participation in the trial may affect the trial results or their own safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of gonadal function indexes from baseline: including LH, FSH, estradiol, progesterone, prolactin, total testosterone, free testosterone and SHBG.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of body weight and body mass index (BMI) from baseline; | — |
Countries
China
Contacts
Public ContactQing Miao
Huashan Hospital, Fudan University
Outcome results
None listed